- Home
- SVRN vs EDSA Comparison
SVRN vs EDSA Comparison
Compare SVRN & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SVRN | EDSA |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | Greece | Canada |
| Employees | 87 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0M | 7.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | SVRN | EDSA |
|---|---|---|
| Price | $0.22 | $7.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 5.4M | ★ 7.7M |
| Earning Date | 04-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.23 | $0.72 |
| 52 Week High | $1.47 | $9.37 |
Technical Indicators
Market Signals| Indicator | SVRN | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 29.61 | 71.78 |
| Support Level | N/A | $1.71 |
| Resistance Level | $0.84 | $8.74 |
| Average True Range (ATR) | 0.07 | 1.52 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 5.15 | 71.99 |
Price Performance
Historical ComparisonAbout SVRN OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.